Lovenox ANDA Approval In 2008 Is “Not Out Of Reach,” Momenta CEO Wheeler Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Chief exec optimistic that FDA will not require any additional clinical trials to move filing forward.
You may also be interested in...
Lovenox Generics Might Be Slowed In U.S. Because Of EU Guidance, Sanofi Hopes
Sanofi-Aventis says an emerging European guideline prescribing clinical trials for low molecular weight heparin generics could sway FDA as it considers copies of its clot-busting blockbuster Lovenox
Lovenox Generics Might Be Slowed In U.S. Because Of EU Guidance, Sanofi Hopes
Sanofi-Aventis says an emerging European guideline prescribing clinical trials for low molecular weight heparin generics could sway FDA as it considers copies of its clot-busting blockbuster Lovenox
FDA Cites Immunogenicity Concerns In “Not Approvable” Letter For Momenta/Sandoz’s Lovenox Generic
Firm is “confident” no immunogenicity differences will arise, Momenta CEO Wheeler says.